Clinical Trial

Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With Polyangiitis

Study acronym: OBI-WAN
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of obinutuzumab to induce clinical and serological remission in patients with relapsing PR3-ANCA granulomatosis with polyangiitis.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-15.
Status change: Not Yet Recruiting → Recruiting 2026-03-04
Trial Details
NCT Number NCT06940661
Lead Sponsor Assistance Publique - Hôpitaux de Paris
Collaborators: URC-CIC Paris Descartes Necker Cochin
Conditions Granulomatosis With Polyangiitis
Enrollment 33 participants
Start Date 2025-12-19
Primary Completion 2027-12 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2026-03-06